Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ITM Isotope Technologies Munich SE

ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Participate in Upcoming Investor Conferences
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance Innovative Radiopharmaceutical Cancer Treatments
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at Upcoming Radiopharmaceutical Investor Conferences in New York City
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Obtains Manufacturing License in the U.S.
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Appoints Roger Estafanos as U.S. General Manager and Expands Presence with Opening of U.S. Headquarters in Princeton, New Jersey
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at the 41st Annual J.P. Morgan Healthcare Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM: Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Multiplies Production Capacity for its n.c.a. Lutetium-177
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.